
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.
AMMAN, Jordan — (ARAB NEWSWIRE) — تدخل المجموعة العربية للعناية بأمراض الكلى (ARCG) مرحلة جديدة…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
News China’s National Medical Products Administration (NMPA) has authorized an implantable brain-computer interface (BCI) designed to help people with severe…
News Ginkgo Bioworks has introduced the Virtual Cell Pharmacology Initiative (VCPI) through its Ginkgo Datapoints division, creating what it describes…
The hefty funding will support a U.S. and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed…
A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow…
Sign in to your account